Coronary Artery Disease (CAD): Beta Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) (NQF 0070)

Similar documents
Heart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or

Heart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or

Diabetes: HbA1c Poor Control (NQF 0059)

Childhood Immunization Status (NQF 0038)

Childhood Immunization Status (NQF 0038)

Weight Assessment and Counseling for Children and Adolescents (NQF 0024)

High Performance Network Quality Criteria for Designation

Measure Information Form

MEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache

2017 CMS Web Interface

2018 CMS Web Interface

2018 CMS Web Interface

2018 CMS Web Interface

2017 CMS Web Interface

2017 CMS Web Interface

2017 CMS Web Interface

Cardiac Rehabilitation Services

2018 CMS Web Interface

NQF 0075 Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control

2018 CMS Web Interface

2017 CMS Web Interface

CSHCN Services Program Benefits to Change for Outpatient Behavioral Health Services Information posted November 10, 2009

Echocardiography Diagnostic Accuracy

2018 CMS Web Interface

NIA Magellan 1 Spine Care Program Interventional Pain Management Frequently Asked Questions (FAQs) For Medicare Advantage HMO and PPO

2018 CMS Web Interface

CLINICAL MEDICAL POLICY

Ischemic heart disease (angina/chest pain)

LTCH QUALITY REPORTING PROGRAM

National Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQ s) For PA Health & Wellness Providers

BP Thresholds for Medical Review

Swindon Joint Strategic Needs Assessment Bulletin

National Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Louisiana Healthcare Connections Providers

National Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Managed Health Services (MHS)

EASTERN ARIZONA COLLEGE Advanced Cardiovascular Life Support

2017 CMS Web Interface

2018 CMS Web Interface

WARNING: FATAL AND SERIOUS TOXICITIES: SEVERE DIARRHEA AND CARDIAC TOXICITIES

Completing the NPA online Patient Safety Incident Report form: 2016

2017 CMS Web Interface

UNM SRMC SLEEP MEDICINE CLINICAL PRIVILEGES.

Michigan Primary Care Transformation Project Performance Incentive Technical Manual

Emergency Department Performance Measures

EASTERN ARIZONA COLLEGE Advanced Cardiac Life Support Renewal

Hospital Performance Series

Obesity/Morbid Obesity/BMI

Wound Care Equipment and Supply Benefits to Change for Texas Medicaid July 1, 2018

CDC Influenza Division Key Points MMWR Updates February 20, 2014

SECTION O. MEDICATIONS

HEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING. Public Health Relevance. Highlights.

Waterloo Wellington Rehabilitative Care System Integrated Care Pathway for STROKE Stream of Care HYPERACUTE URGENT TIA and SECONDARY STROKE PREVENTION

Clinical Study Synopsis

Lyme Disease Surveillance in North Carolina

Benefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria

COPD Outreach Program

Solid Organ Transplant Benefits to Change for Texas Medicaid

Nova Scotia Guidelines for Acute Coronary Syndromes (2008) QUICK REFERENCE MARCH Supported by unrestricted educational grants from:

National Hospital Inpatient Quality Reporting Measures Specifications Manual Release Notes

Family Medicine Clinical Pharmacy Forum Vol. 3, Issue 5 (September/October 2007)

Breast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)

1.11 INSULIN INFUSION PUMP MANAGEMENT INPATIENT

Significance of Chronic Kidney Disease in 2015

Cognitive enhancers for the treatment of Alzheimer s disease

Measure Specific Guidelines for Comprehensive Diabetes Care (CDC)

Bariatric Surgery FAQs for Employees in the GRMC Group Health Plan

2017 PEPFAR Data and Systems Applied Learning Summit Day 2: MER Analytics/Available Visualizations, Clinical Cascade Breakout Session TB/HIV EXERCISE

CDC Influenza Technical Key Points February 15, 2018

2018 CMS Web Interface

Package leaflet: Information for the user. Fragmin Graduated Syringe 10,000 IU/ml Solution for Injection dalteparin sodium

Urinary Retention: Inability to pass urine despite the presence of urine in the bladder.

2018 CMS Web Interface

ACRIN 6666 Screening Breast US Follow-up Assessment Form

Hospital Preparedness Checklist

You may have a higher risk of bleeding if you take warfarin sodium tablets and:

Field Epidemiology Training Program

Percutaneous Nephrolithotomy (PCNL)

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

Meaningful Use Roadmap Stage Edition Eligible Hospitals

Podcast Transcript Title: Common Miscoding of LARC Services Impacting Revenue Speaker Name: Ann Finn Duration: 00:16:10

KP National Cardiovascular Risk and Dyslipidemia Management Guideline

STATISTICAL ANALYSIS PLAN. Addendum 1 (V 1 12SEP2015)

Immunisation and Disease Prevention Policy

o Procedures performed o Diagnoses Identified o Certain devices/equipment/supplies acquired for patient

Nutrition Care Process Model Tutorials. Nutrition Monitoring & Evaluation: Overview & Definition. By the end of this module, the participant will:

National Hospital Inpatient Quality Reporting Measures Specifications Manual Release Notes

A Phase I Study of CEP-701 in Patients with Refractory Neuroblastoma NANT (01-03) A New Approaches to Neuroblastoma Therapy (NANT) treatment protocol.

National Hospital Inpatient Quality Reporting Measures Specifications Manual Release Notes

ALCAT FREQUENTLY ASKED QUESTIONS

2018 Medical Association Poster Symposium Guidelines

2013 DATA COLLECTION GUIDE Summary Data Submission. Optimal Asthma Care. (07/01/2012 to 06/30/2013 Dates of Service)

ICD-10-CM Coding Basics Chapter Specifics

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

National Hospital Inpatient Quality Reporting Measures Specifications Manual Release Notes

QUALITY AND SAFETY MEASURES UPDATE January 2016

Osteoporosis Fast Facts

Vaccine Information Statement: PNEUMOCOCCAL CONJUGATE VACCINE

Trust Guideline for Urgent Brain Imaging and Management of Suspected Subarachnoid Haemorrhage

Continuous Positive Airway Pressure (CPAP) and Respiratory Assist Devices (RADs) including Bi-Level PAP

Transcription:

Crnary Artery Disease (CAD): Beta Blcker Therapy fr CAD Patients with Prir Mycardial Infarctin (MI) (NQF 0070) EMeasure Name Crnary Artery Disease EMeasure Id Pending (CAD): Beta Blcker Therapy fr CAD Patients with Prir Mycardial Infarctin (MI) Versin Number 1 Set Id Pending Available Date N infrmatin Measurement Perid January 1, 20xx thrugh December 31, 20xx Measure Steward American Medical Assciatin Physician Cnsrtium fr Perfrmance Imprvement Endrsed by Descriptin Measure scring Measure type Ratinale Clinical Recmmendatin Statement Natinal Quality Frum Percentage f patients aged 18 years and lder with a diagnsis f CAD and prir MI wh were prescribed beta blcker therapy. Prprtin Prcess In the absence f cntraindicatins, beta blcker therapy has been shwn t reduce the risk f a recurrent MI and decrease mrtality fr thse patients with a prir MI. Chrnic Stable Angina: Class I Beta blckers as initial therapy in the absence f cntraindicatins in patients with prir MI. Class I Beta blckers as initial therapy in the absence f cntraindicatins in patients withut prir MI (ACC/AHA/ACP ASIM). Unstable Angina and Nn ST Segment Elevatin Mycardial Infarctin: Class I Drugs required in the hspital t cntrl ischemia shuld be cntinued after hspital discharge in patients wh d nt underg crnary revascularizatin, patients with unsuccessful revascularizatin, r patients with recurrent symptms after revascularizatin. Upward r dwnward titratin f the dses may be required. Class I Beta blckers in the absence f cntraindicatins (ACC/AHA). Acute Mycardial Infarctin: Class I All but lw risk patients withut a clear cntraindicatin t ß adrenceptr blcker therapy. Treatment shuld begin within a few days f the event (if nt initiated acutely) and cntinue indefinitely. Class IIa Lw risk patients withut a clear cntraindicatin t ß adrenceptr blcker therapy. Survivrs f nn ST elevatin MI. Class IIb Patients with mderate r severe LV failure r ther relative cntraindicatins t ß adrenceptr blcker therapy, prvided they can be mnitred clsely (ACC/AHA). References Althugh n study has determined if lng term ß adrenceptr blcker therapy shuld be administered t survivrs f MI wh subsequently have satisfactrily undergne revascularizatin, there is n reasn t believe that these agents act differently in crnary patients wh have undergne revascularizatin (ACC/AHA).

Definitins Table f Cntents Ppulatin criteria Data criteria (QDS Data Elements) Summary calculatin Please refer t the spreadsheet fr this measure fr detail regarding data criteria and cde lists. Ppulatin criteria Initial Patient Ppulatin = Denminatr = Numeratr = Exclusins = Patient characteristic: birth date (age) >= 18 years; OR: Diagnsis active: crnary artery disease n MI ; OR: Prcedure perfrmed: cardiac surgery ; >= 2 cunt(s) f: OR: Encunter: encunter nursing facility ; OR: Encunter: encunter utpatient ; OR: >= 1 cunt(s) f Encunter: encunter inpatient discharge ; All patients in the initial patient ppulatin; Diagnsis reslved: mycardial infarctin ; OR: Medicatin rder: beta blcker therapy ; OR: Medicatin active: beta blcker therapy ; OR: Diagnsis active: arrhythmia ; OR: Diagnsis active: hyptensin ; OR: Diagnsis active: asthma ; OR: Diagnsis active: bradycardia ; OR: Diagnsis active: atresia and stensis f arta ; OR: Diagnsis active: atriventricular blck ; AND NOT: OR: Diagnsis active: cardiac pacer in situ ; OR: Device applied: cardiac pacer ; OR: Prcedure perfrmed: cardiac mnitring ; OR: Medicatin adverse event: beta blcker therapy ;

OR: Medicatin allergy: beta blcker therapy ; OR: Medicatin intlerance: beta blcker therapy ; OR: Medicatin nt dne: medical reasn ; OR: Medicatin nt dne: patient reasn ; OR: Medicatin nt dne: system reasn ; OR: >1 cnsecutive cunt(s) f Physical exam finding: heart rate, < 50 bpm; Data criteria (QDS Data Elements) Initial Patient Ppulatin = Denminatr = Numeratr = Exclusins = "Patient characteristic: birth date using birth date cde list befre the beginning f the measurement perid ; Diagnsis active: crnary artery disease n MI using crnary artery disease n MI cde list gruping befre r simultaneusly t Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Prcedure perfrmed: cardiac surgery using cardiac surgery cde list gruping befre r simultaneusly t the Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Encunter: encunter nursing facility using encunter nursing facility cde list during the measurement perid ; Encunter: encunter utpatient using encunter utpatient cde list during the measurement perid ; Encunter: encunter inpatient discharge using encunter inpatient discharge cde list during the measurement perid ; All patients in the initial patient ppulatin; Diagnsis reslved: mycardial infarctin using mycardial infarctin cde list gruping befre r simultaneusly t Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Medicatin rder: beta blcker therapy using beta blcker therapy cde list during the measurement perid ; Medicatin active: beta blcker therapy using beta blcker therapy cde list during the measurement perid ; Diagnsis active: arrhythmia using arrhythmia cde list gruping befre r simultaneusly t Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Diagnsis active: hyptensin using hyptensin cde list gruping befre r simultaneusly t Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Diagnsis active: asthma using asthma cde list gruping befre r simultaneusly t Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ;

Diagnsis active: bradycardia using bradycardia cde list gruping befre r simultaneusly t Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Diagnsis active: atresia and stensis f arta using atresia and stensis f arta cde list gruping befre r simultaneusly t Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Diagnsis active: atriventricular blck using atriventricular blck cde list gruping befre r simultaneusly t Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Diagnsis active: cardiac pacer in situ using cardiac pacer in situ cde list gruping befre r simultaneusly t Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Device applied: cardiac pacer device using cardiac pacer device cde list befre r simultaneusly t Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Prcedure perfrmed: cardiac mnitring using cardiac mnitring cde list befre r simultaneusly t Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Medicatin adverse event: beta blcker therapy using beta blcker therapy cde list befre r simultaneusly t En cunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Medicatin allergy: beta blcker therapy using beta blcker therapy cde list befre r simultaneusly t En cunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Medicatin intlerance: beta blcker therapy using beta blcker therapy cde list befre r simultaneusly t En cunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Medicatin nt dne: medical reasn using medical reasn cde list fr Medicatin rder: beta blcker therapy OR Medicatin active: beta blcker therapy ; Medicatin nt dne: patient reasn using patient reasn cde list fr Medicatin rder: beta blcker therapy OR Medicatin active: beta blcker therapy ; Medicatin nt dne: system reasn using system reasn cde list fr Medicatin rder: beta blcker therapy OR Medicatin active: beta blcker therapy ; Physical exam finding: heart rate using heart rate cde list befre r simultaneusly t Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Summary Calculatin Calculatin is generic t all measures: Calculate the final denminatr by adding all that meet denminatr criteria. Subtract frm the final denminatr all that d nt meet numeratr criteria yet als meet exclusin criteria. Nte sme measures d nt have exclusin criteria. The perfrmance calculatin is the number meeting numeratr criteria divided by the final denminatr. Fr measures with multiple patient ppulatins, repeat this prcess fr each patient ppulatin and reprt each result separately.

Fr measures with multiple numeratrs, calculate each numeratr separately within each ppulatin using the paired exclusin. Measure set CLINICAL QUALITY MEASURE SET 2011 2012